Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Afinitor Significantly Increased PFS in Women with Advanced Breast Cancer: Novartis
October 3, 2011
- Asahi Kasei Pharma, tella Announce Joint R&D Agreement for Cell Processing Equipment
October 3, 2011
- Maruho Establishes US Subsidiary
October 3, 2011
- Ono: Corebeta for Inj. 12.5 mg for Improving Image Quality in Coronary CT Angiography
October 3, 2011
- Novartis Pharma: COPD Treatment Onbrez Inhalation Capsules
October 3, 2011
- Nesina Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
October 3, 2011
- Pfizer Starts New Online Promotion with MedPeer
September 30, 2011
- MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars
September 30, 2011
- Takeda Files NDA for Hyperlipidemia Treatment TAK-085 in Japan
September 30, 2011
- Imatinib Significantly Improves Walking Distance in Patients with PAH: Novartis
September 30, 2011
- Takeda President Hasegawa Eyes Joint Research with Chinese Companies
September 29, 2011
- Santen to Acquire French Drugmaker, Strengthen R&D
September 29, 2011
- Ono, Univ. of Tokyo Sign Joint Research Agreement for Drug Discovery Target Identification
September 29, 2011
- MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
- NBI Releases Latest PMS Results for Prazaxa
September 28, 2011
- Rivaroxaban Recommended for Approval in EU: Bayer
September 28, 2011
- Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
- Kowa, NanoCarrier Announce License Agreement for Epirubicin Micelle
September 28, 2011
- Dry Eye Treatment Mucosta Ophthalmic Suspension Approved: Otsuka
September 27, 2011
- Teva to Resolve Joint Venture with Kowa, Acquire 100% Stake in Teva-Kowa
September 27, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…